Home › Preeclampsia › NCT06333652

Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Clinical Trial on the Use of Ravulizumab in Pregnancies Complicated by Severe Hypertensive Disorders

Who can join

Ages 18 to 50 · Women

Inclusion Criteria:

* Individuals with \< 34 0/7 weeks of gestation.
* Individuals with severe preeclampsia or HELLP features.

Exclusion Criteria:

* Pregnant female patients presenting with disseminated intravascular coagulopathy (DIC).
* Individuals with non-reassuring fetal status requiring delivery, non-viable fetuses, previable pregnancy (\<23 0/7 weeks gestation), stroke, in utero fetal demise, known atypical hemolytic uremic syndrome, familial or acquired thrombocytopenia purpura, paroxysmal nocturnal hemoglobinuria, allergy to Ravulizumab, inability or unwillingness to sign informed consent.

About the study

The researchers are testing a medication named ravulizumab for the treatment of severe preeclampsia and Hemolysis, Elevated Liver enzymes, Low Platelets (HELLP) syndrome.

What is being tested

• Ravulizumab (drug)

Sponsor: Mayo Clinic · Participants: 14 · Started: Sep 1, 2026

Contact the study team

• Gonzalez Suarez · Phone: 507-284-2511

Official record on ClinicalTrials.gov — NCT06333652

Locations in the U.S.

Conditions

• Preeclampsia

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.